ghrelin and glp-1 Ghrelin, CCK, GLP-1, PYY(3–36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB | Physiological Reviews ghrelin and glp 1 Figure

What most articles get wrong about GLP-1 drug classification The single most common error in published GLP-1 content is classifying tirzepatide as a GLP-1 receptor agonist

Its a truly remarkable finding for an 8 year old drug designed for diabetes: Novo Nordisk is currently running two large Phase 3 trials to investigate the effect of GLP-1 drugs on Alzheimer's disease, based on early data suggesting reduced neuroinflammation, improved cognition and function, and enhanced memory, as well as trials in which GLP-1 drugs appeared to substantially reduce dementia rates in diabetes patients

Genne P, Dimanche-Boitrel MT, Mauvernay RY, et al

Garzorz, N

Secondary outcomes were changes in HbA1c, body weight, body composition, lipid profile, glucagon level, the HOMA2-IR and HOMA2-% indices, and the association of these variables with the glucose infusion rate (GIR)